The programme is designed to discuss key industry trends and milestones. It will feature more than 8 hours of high-level keynotes and panel discussions covering the latest trends in Pharma and Biotech BD, modalities, targets, and investment. This will be available on demand for the virtual audience the week after ASCO. Additionally, there will be pre-arranged in-person and virtual meetings, live and on demand company showcases and a reception.

Click here to register!

Attend our presentations

mRNA and Cancer Vaccines: Present Developments & Future Imagined

Time: 10:35am CDT
Day: June 2, 2023


  • Jeffrey Bockman, PhD, Expert Advisor, EVP, Oncology, Lumanity
  • Kaveri Pohlman, Director, Biotechnology Equity Research, BTIG, LLC


  • Andrew Allen, Co-Founder, President & CEO, Gritstone bio, Inc.
  • Carlos de Sousa, CEO, Ultimovacs ASA
  • Johanna Kaufmann, EVP Oncology, Codagenix Inc. Marina Udier, CEO, Nouscom AG
  • Niranjan Sardesai, Founder, President & CEO, Geneos Therapeutics

Competing in the Cell & Gene Therapy Space

Time: 11:30am CDT
Day: June 2, 2023


  • Michael Rice, MS, MBA, Expert Advisor, SVP, Cell and Gene Therapy


  • Daniel Teper, Co-Founder, Chairman & CEO, Cytovia Therapeutics, LLC
  • Deborah Rathjen, CEO, Carina Biotech
  • Katrien Reynders-Frederix, CEO, Pan Cancer T B.V.
  • Paul Lammers, President & CEO, Triumvira Immunologics, Inc.
  • William Ho, President & CEO, IN8bio, Inc.